



SATELLITE SYMPOSIUM SUPPORTED BY CELGENE

13:30 – 15:30

Hall 15.2 (Stockholm)

CHANGING THE TREATMENT PARADIGM IN MYELODYSPLASTIC SYNDROMES

Chair: W-K Hofmann (University Hospital Mannheim, Mannheim, Germany)

Co-Chair: V Santini (Policlinico di Careggi, Florence, Italy)

13:30 – 13:45

■ **WELCOME AND INTRODUCTION**

W-K Hofmann (University Hospital Mannheim, Mannheim, Germany)

13:45 – 14:10

■ **AZACITIDINE: FIRST-IN-CLASS HYPOMETHYLATING AGENT**

P Fenaux (Hôpital Avicenne, Paris, France)

14:10 – 14:35

■ **PROLONGED SURVIVAL WITH AZACITIDINE IN PATIENTS WITH HIGH- OR INTERMEDIATE-2-RISK MYELODYSPLASTIC SYNDROMES**

V Santini (Policlinico di Careggi, Florence, Italy)

14:35 – 15:00

■ **ACHIEVING TRANSFUSION INDEPENDENCE IN PATIENTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES**

A Giagounidis (St Johannes Hospital, Duisburg, Germany)

15:00 – 15:25

■ **PANEL DISCUSSION: CURRENT AND FUTURE TREATMENTS OF MYELODYSPLASTIC SYNDROMES**

Moderator: V Santini (Policlinico di Careggi, Florence, Italy)

15:25 – 15:30

■ **CLOSING REMARKS**

W-K Hofmann (University Hospital Mannheim, Mannheim, Germany)